desmopressin acetate


Also found in: Medical, Acronyms, Wikipedia.
Related to desmopressin acetate: diabetes insipidus

des·mo·pres·sin acetate

 (dĕs′mə-prĕs′ĭn)
n.
A synthetic analog of vasopressin used therapeutically as an antidiuretic and in the management of bleeding in individuals with some forms of hemophilia and von Willebrand disease.

[des(a)m(in)o-, lacking an amine group (des-, variant of de- + amino-) + (vaso)pressin.]
References in periodicals archive ?
Amring is already invested in desmopressin acetate, a peptide-based drug that can treat diabetes insipidus, as well as certain bleeding disorders and bed-wetting problems.
Noctiva is a low-dose formulation of desmopressin acetate administered through a patented intranasal delivery system.
The patient received desmopressin acetate tablets (1.
Hematology consultation was obtained for the administration of desmopressin acetate (DDAVP) for correction of her platelet function after which she underwent an uncomplicated primary cesarean section.
Here, a very low birth weight premature infant who developed central diabetes insipidus secondary to pituitary hemorrhage in the newborn period and was treated successfully with intranasal desmopressin acetate was presented.
Desmopressin acetate, a synthetic analogue of the natural pituitary hormone ADH, is used in the management of central diabetes insipidus.
Eleven of 19 patients treated with aminocaproic acid, desmopressin acetate, or oral contraceptives achieved menstrual control.
Intranasal formulations of desmopressin acetate are no longer indicated for treating primary nocturnal enuresis because of the risk of severe hyponatremia and seizures associated with these products when used for this indication, according to the Food and Drug Administration.
BY ELIZABETH MECHCATIE Senior Writer Intranasal formulations of desmopressin acetate are no longer indicated for treating primary nocturnal enuresis because of the risk of severe hyponatremia and seizures associated with these products when used for this indication, according to the Food and Drug Administration.
Some patients with von Willebrand Disease and some patients with mild hemophilia A may respond to desmopressin acetate (DDAVP), a synthetic hormone.
These include moisture-sensing alarms and motivational therapies, as well as pharmacologic options such as desmopressin acetate.
In addition to parenteral fluid replacement, 2 [micro]g desmopressin acetate (dDAVP) was given subcutaneously.